Capadiso, Rhian .

HRN: 28-13-80  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/25/2025
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
11/25/2025
12/02/2025
PO
3mL
2x/day
AGE With Mod DHN
Checking Final Appropriateness 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: